同行评审出版物
Diabetes, Obesity and Metabolism
Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study
了解更多
Diabetes Therapy
Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels
了解更多
Nature Communications
2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
了解更多
Diabetes
Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
了解更多
Nature Medicine
2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.
了解更多
Nature Medicine
2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
了解更多
Nature Medicine
2022 May, Nature Medicine: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
了解更多
Clinical and Translational Science
2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.
了解更多
Global Journal of Obesity, Diabetes and Metabolic Syndrome
2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China
了解更多
Diabetes, Obesity and Metabolism
2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
了解更多
Clinical Pharmacokinetics
2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics
了解更多
Lancet Diabetes Endocrinology
2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?
了解更多
Lancet Diabetes Endocrinology
2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
了解更多
Journal of Diabetes Research
2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus
了解更多
Drug Design, Development and Therapy
2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
了解更多
Intractable & Rare Diseases Research
2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ‒ Turning challenges into opportunities
了解更多
Clinical Pharmacokinetics
2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process
了解更多
Intractable & Rare Diseases Research
2015 / Intractable & Rare Diseases Research：Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities
了解更多
搜索
我们如何使用Cookies
尊龙凯时医药使用 Cookie 来改进网站的使用。继续使用本网站即表示您同意使用这些 Cookie。如需了解更多关于 Cookie 的信息，请阅读我们的隐私声明。
全部接受
x